Trials / Terminated
TerminatedNCT01341340
The ABSORB BTK (Below The Knee) Clinical Investigation
A Clinical Evaluation of the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS) for the Treatment of Subjects With Critical Limb Ischemia (CLI) From Occlusive Vascular Disease of the Tibial Arteries
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the ABSORB BTK Clinical Investigation is to evaluate the safety and efficacy of the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS) in subjects with critical limb ischemia (CLI) following percutaneous transluminal angioplasty (PTA) of the tibial arteries.
Conditions
- Atherosclerosis
- Peripheral Artery Disease
- Peripheral Vascular Disease
- PAD
- Claudication
- Critical Limb Ischemia
- Lower Limb Disease
- Peripheral Arterial Occlusive Disease
- PAOD
- PVD
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Everolimus Eluting BVS | Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS) |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2012-11-01
- Completion
- 2012-11-01
- First posted
- 2011-04-25
- Last updated
- 2019-04-11
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT01341340. Inclusion in this directory is not an endorsement.